FDA Breakthrough Leverage DirectSync Surgical's FDA Breakthrough Device designation for a spinal fusion smart implant to accelerate engagement with hospitals and surgical centers pursuing innovative, faster-to-market solutions and premium patient outcomes.

Clinical Value Highlight the osteoinductive piezoelectric biomaterials and smart implant approach as a differentiator to orthopedic departments seeking cost-effective, bone-healing technologies that can reduce length of stay and improve post-op recovery.

Strategic Partnerships Target early adopters and key opinion leaders in spine and orthopedics for co-development, clinical trials, and pilot programs to validate real-world outcomes and build credibility with larger medical device companies.

Growth Readiness Position revenue growth as a signal of scalable demand; align messaging with emerging market trends toward smart implants, value-based care, and streamlined care episodes to attract investors and large distributors.

Funding & Support Offer bundled solutions including training, integration with hospital IT, and post-market surveillance services to ease adoption, given the company's small team size and need for scalable support partnerships.